Targeting a specific protein linked to Alzheimer's disease in individuals with Down syndrome
Investigating and targeting apolipoprotein E4 in Down syndrome-associated Alzheimer's disease
['FUNDING_OTHER'] · UNIVERSITY OF COLORADO DENVER · NIH-10658660
This study is looking at how a protein called apoE4 affects brain health in people with Down syndrome who may develop Alzheimer's disease, and it aims to find safe medications that could help protect their brain cells from damage.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF COLORADO DENVER (nih funded) |
| Locations | 1 site (Aurora, UNITED STATES) |
| Trial ID | NIH-10658660 on ClinicalTrials.gov |
What this research studies
This research investigates the role of apolipoprotein E4 (apoE4) in the development of Alzheimer's disease among individuals with Down syndrome. It focuses on understanding how this protein contributes to neurodegeneration and aims to identify potential therapies that can inhibit its harmful effects. The researchers have developed a laboratory test to screen existing medications for their ability to block the toxic actions of apoE4 on brain cells. By utilizing compounds that have already been tested for safety in other conditions, the study seeks to expedite the development of effective treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with Down syndrome, particularly those who may be at risk for developing Alzheimer's disease due to genetic factors.
Not a fit: Patients without Down syndrome or those who do not carry the apoE4 allele may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that significantly reduce the risk or severity of Alzheimer's disease in individuals with Down syndrome.
How similar studies have performed: Previous research has shown promise in targeting apoE in Alzheimer's disease, suggesting that this approach could be effective, although the specific application to Down syndrome is less explored.
Where this research is happening
Aurora, UNITED STATES
- UNIVERSITY OF COLORADO DENVER — Aurora, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: JOHNSON, NOAH RAY — UNIVERSITY OF COLORADO DENVER
- Study coordinator: JOHNSON, NOAH RAY
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Alzheimer disease dementia, Alzheimer syndrome